Navigation Links
Sysmex America Begins Distribution of CellaVision® DM1200

MUNDELEIN, Ill., July 20 /PRNewswire/ -- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced the addition of the CellaVision® DM1200 cell image analysis analyzer to the Sysmex hematology product offering.  The DM1200 enables Sysmex America to meet the growing demand for automated cell image analysis, which improves both the quality of results and the productivity of laboratories performing mid-volume testing.    

The CellaVision® DM1200 opens up new ways of handling manual differentials traditionally performed on a microscope by automatically performing a preliminary differential count on peripheral blood. The analyzer pre-classifies the white blood cells, pre-characterizes parts of the red morphology and provides functionality for platelet estimation. By automating the manual differential, laboratories can experience enhanced turnaround times without sacrificing quality.  Its high degree of automation allows for an escalating workload without increasing labor.

"The CellaVision DM1200, which locates, identifies, and pre-classifies blood cells by means of automatic microscopy and advanced image processing, greatly enhances Sysmex America's hematology product offering.  We trust this addition to our hematology portfolio will serve our customers well as they continue to navigate through a challenging health care environment," said John Kershaw, President & CEO, Sysmex America, Inc.    

Sysmex America and CellaVision first initiated their working relationship in 2004.  Today, Sysmex Corporation and CellaVision have an extended and broadened working relationship via the completion of a recent global distribution agreement.  The agreement gives Sysmex a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide.  As of April 1, 2010, the non-exclusive agreement comprises all international markets but Canada.  

About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.  The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit  CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems.  Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.  For more information about Sysmex, please visit

SOURCE Sysmex America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OhioHealth Installs Newest Version of Sysmexs Hematology Middleware, Sysmex WAM(TM) 4.0
2. Sysmex America Adds Industry Veteran to Company Leadership
3. Sysmex America Honored Second Consecutive Year as a Company That Cares
4. Sysmex America Announces Executive Leadership Changes
5. Sysmex America Announces Amerinet Urinalysis Contract
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. Aspirin Named 8th World Wonder by Majority of Americans
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):